Co-Authors
This is a "connection" page, showing publications co-authored by AHMED KASEB and EUGENE JON KOAY.
Connection Strength
2.390
-
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. medRxiv. 2024 Sep 12.
Score: 0.247
-
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. 2024 Jun 03; 29(6):e803-e810.
Score: 0.242
-
Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
Score: 0.240
-
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark. 2024; 41(1):83-91.
Score: 0.235
-
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers (Basel). 2023 Oct 07; 15(19).
Score: 0.231
-
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1195-1207.
Score: 0.201
-
Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma. 2021; 8:57-69.
Score: 0.193
-
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
Score: 0.162
-
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
Score: 0.150
-
Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clin Transl Radiat Oncol. 2017 Jun; 4:39-45.
Score: 0.149
-
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. Mol Cancer. 2024 Aug 02; 23(1):156.
Score: 0.061
-
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. medRxiv. 2024 Mar 15.
Score: 0.060
-
Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg. 2023 09; 27(9):1867-1875.
Score: 0.056
-
Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel). 2022 Apr 09; 14(8).
Score: 0.052
-
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019 04; 133:54-61.
Score: 0.042
-
Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer. 2017 04 15; 123(8):1354-1362.
Score: 0.036
-
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016 Jan 20; 34(3):219-26.
Score: 0.033